Guidelines on the management of secondary prophylaxis of vascular events in stable patients in primary care

Atherothrombosis, thrombus formation superimposed on an existing atherosclerotic plaque, is an acute process leading to ischaemic events such as myocardial infarction, stroke and critical limb ischaemia. Patients presenting with clinical conditions associated with atherothrombosis are at increased risk of subsequent vascular events. The beneficial effect of antiplatelet therapies for short‐term and long‐term secondary prevention of atherothrombotic events has been established. These guidelines aim to provide evidence‐based recommendations that will assist in the antiplatelet‐mediated secondary prophylaxis of vascular events in patients with stable cardiovascular disease treated in the primary healthcare setting. Medline and the Cochrane library were accessed using free‐text strategies in the domains of antiplatelet agents and antithrombotics. Development of the guidelines was driven by a series of Steering Committee meetings, in which the quality of relevant studies was assessed and identified using narrative summary. These guidelines present evidence and recommendations for the treatment of numerous atherothrombotic indications depending on individual patient circumstances.

[1]  V. Fuster,et al.  Platelet-active drugs: the relationships among dose, effectiveness, and side effects. , 2004, Chest.

[2]  Eric J Topol,et al.  Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. , 2002, JAMA.

[3]  G. Lip,et al.  Antithrombotic therapy for atrial fibrillation , 2002, BMJ : British Medical Journal.

[4]  A. Mattioli,et al.  Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients , 2002, BMJ : British Medical Journal.

[5]  R. Peto,et al.  Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients , 2002, BMJ : British Medical Journal.

[6]  S. Yusuf,et al.  Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. , 2001, The New England journal of medicine.

[7]  R. Harbour,et al.  A new system for grading recommendations in evidence based guidelines , 2001, BMJ : British Medical Journal.

[8]  G. Lowe,et al.  Lipoprotein (a) and development of intermittent claudication and major cardiovascular events in men and women: the Edinburgh Artery Study. , 2001, Atherosclerosis.

[9]  R. Gibbons,et al.  ACC/AHA Guidelines for Percutaneous Coronary Intervention (Revision of the 1993 PTCA Guidelines)—Executive Summary , 2001 .

[10]  M. Roncaglioni Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general Practice , 2001, The Lancet.

[11]  S. Yusuf,et al.  The Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial programme; rationale, design and baseline characteristics including a meta-analysis of the effects of thienopyridines in vascular disease. , 2000, European heart journal.

[12]  J. W. Schaeffer,et al.  ACC/AHA guidelines for the management of patients with unstable angina and non–st-segment elevation myocardial infarction: A report of the american college of cardiology/ american heart association task force on practice guidelines (committee on the management of patients with unstable angina) , 2000 .

[13]  M. Bertrand,et al.  Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting : the clopidogrel aspirin stent international cooperative study (CLASSICS). , 2000, Circulation.

[14]  E. Schryver Design of ESPRIT: An International Randomized Trial for Secondary Prevention after Non-Disabling Cerebral Ischaemia of Arterial Origin , 2000 .

[15]  E. de Schryver Design of ESPRIT: An International Randomized Trial for Secondary Prevention after Non-Disabling Cerebral Ischaemia of Arterial Origin , 2000, Cerebrovascular Diseases.

[16]  H. Roskamm,et al.  A randomized comparison of clopidogrel and aspirin versus ticlopidine and aspirin after the placement of coronary-artery stents. , 2000, Circulation.

[17]  R. Ligon,et al.  Clopidogrel as adjunctive antiplatelet therapy during coronary stenting. , 1999, Journal of the American College of Cardiology.

[18]  J. Caro,et al.  Generalizing the results of clinical trials to actual practice: the example of clopidogrel therapy for the prevention of vascular events. CAPRA (CAPRIE Actual Practice Rates Analysis) Study Group. Clopidogrel versus Aspirin in Patients at Risk of Ischaemic Events. , 1999, The American journal of medicine.

[19]  D. Fitzgerald,et al.  Ticlopidine and clopidogrel. , 1999, Circulation.

[20]  S. Pocock,et al.  A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. , 1999, The New England journal of medicine.

[21]  R Brian Haynes,et al.  Low-dose and high-dose acetylsalicylic acid for patients undergoing carotid endarterectomy: a randomised controlled trial , 1999, The Lancet.

[22]  J. Moses,et al.  Effectiveness of clopidogrel and aspirin versus ticlopidine and aspirin in preventing stent thrombosis after coronary stent implantation. , 1999, Circulation.

[23]  J. Meyer-Kirchrath,et al.  Cyclooxygenase-2 in human platelets as a possible factor in aspirin resistance , 1999, The Lancet.

[24]  S. Pocock,et al.  A Clinical Trial Comparing Three Antithrombotic-Drug Regimens after Coronary-Artery Stenting , 1998 .

[25]  C. Macaya,et al.  Randomized evaluation of anticoagulation versus antiplatelet therapy after coronary stent implantation in high-risk patients: the multicenter aspirin and ticlopidine trial after intracoronary stenting (MATTIS). , 1998, Circulation.

[26]  E. Fleck,et al.  Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting. The full anticoagulation versus aspirin and ticlopidine (fantastic) study. , 1998, Circulation.

[27]  Joël Ménard,et al.  Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial , 1998, The Lancet.

[28]  J. Mason,et al.  North of England evidence based guideline development project: guideline on the use of aspirin as secondary prophylaxis for vascular disease in primary care , 1998 .

[29]  M. Bell,et al.  Frequency of adverse clinical events in the 12 months following successful intracoronary stent placement in patients treated with aspirin and ticlopidine (without warfarin). , 1998, American Journal of Cardiology.

[30]  Arno W. Hoes,et al.  Peripheral arterial disease in the elderly: The Rotterdam Study. , 1998, Arteriosclerosis, thrombosis, and vascular biology.

[31]  R B D'Agostino,et al.  Intermittent claudication. A risk profile from The Framingham Heart Study. , 1997, Circulation.

[32]  Zheng-Ming Chen,et al.  CAST: randomised placebo-controlled trial of early aspirin use in 20 000 patients with acute ischaemic stroke , 1997, The Lancet.

[33]  Peter Sandercock,et al.  The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19 435 patients with acute ischaemic stroke , 1997, The Lancet.

[34]  S. Shapiro,et al.  Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product , 1996, The Lancet.

[35]  M. Dennis A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee , 1996 .

[36]  H. Diener,et al.  European Stroke Prevention Study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke 1 1 ESPS-2 Writing Committee , 1996, Journal of the Neurological Sciences.

[37]  M. Hadamitzky,et al.  A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. , 1996, The New England journal of medicine.

[38]  J. Knottnerus,et al.  The prevalence of asymptomatic and unrecognized peripheral arterial occlusive disease. , 1996, International journal of epidemiology.

[39]  T. Bowker,et al.  A British Cardiac Society survey of the potential for the secondary prevention of coronary disease: ASPIRE (Action on Secondary Prevention through Intervention to Reduce Events). , 1996, Heart.

[40]  A. Colombo,et al.  A randomized comparison of combined ticlopidine and aspirin therapy versus aspirin therapy alone after successful intravascular ultrasound-guided stent implantation. , 1996, Circulation.

[41]  B. Gage,et al.  Cost-effectiveness of warfarin and aspirin for prophylaxis of stroke in patients with nonvalvular atrial fibrillation. , 1995, Journal of the American Medical Association (JAMA).

[42]  G. Albers,et al.  Atrial fibrillation and stroke. Three new studies, three remaining questions. , 1994, Archives of internal medicine.

[43]  P. Touboul,et al.  Mediterranean alpha-linolenic acid-rich diet in secondary prevention of coronary heart disease , 1994, The Lancet.

[44]  Stroke Investigators Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study , 1994, The Lancet.

[45]  Collaborative overview of randomised trials of antiplatelet therapy - II: Maintenance of vascular graft or arterial patency by antiplatelet therapy , 1994, BMJ.

[46]  Walker,et al.  Collaborative overview of randomised trials of antiplatelet therapy Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients , 1994 .

[47]  D. Waters,et al.  Aspirin Versus Heparin to Prevent Myocardial Infarction During the Acute Phase of Unstable Angina , 1993, Circulation.

[48]  P. Roderick,et al.  The gastrointestinal toxicity of aspirin: an overview of randomised controlled trials. , 1993, British journal of clinical pharmacology.

[49]  J. Slattery,et al.  Atrial fibrillation and stroke: prevalence in different types of stroke and influence on early and long term prognosis (Oxfordshire community stroke project) , 1992, BMJ.

[50]  G. Clagett,et al.  Antithrombotic therapy in peripheral arterial occlusive disease. , 1992, Chest.

[51]  F. Ferris Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report 14. ETDRS Investigators. , 1992, JAMA.

[52]  D. Stevenson,et al.  Aspirin sensitivity. A distressing reaction that is now often treatable. , 1991, Postgraduate medicine.

[53]  M. Laakso,et al.  The European Stroke Prevention Study , 1991, Neurology.

[54]  V. Gebski,et al.  Immediate Postoperative Aspirin Improves Vein Graft Patency Early and Late After Coronary Artery Bypass Graft Surgery: A Placebo‐Controlled, Randomized Study , 1991, Circulation.

[55]  C. Madden Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease: The RISC Group Lancet 336: 827–830 Oct 1990 , 1991 .

[56]  L. Wilkins European Stroke Prevention Study. ESPS Group. , 1990, Stroke.

[57]  G. FitzGerald Ticlopidine in unstable angina. A more expensive aspirin? , 1990, Circulation.

[58]  D. Bergqvist,et al.  Prevention of myocardial infarction and stroke in patients with intermittent claudication; effects of ticlopidine. Results from STIMS, the Swedish Ticlopidine Multicentre Study , 1990, Journal of internal medicine.

[59]  J. Copeland,et al.  Saphenous vein graft patency 1 year after coronary artery bypass surgery and effects of antiplatelet therapy. Results of a Veterans Administration Cooperative Study. , 1989, Circulation.

[60]  P. Elwood,et al.  EFFECTS OF CHANGES IN FAT, FISH, AND FIBRE INTAKES ON DEATH AND MYOCARDIAL REINFARCTION: DIET AND REINFARCTION TRIAL (DART) , 1989, The Lancet.

[61]  H. Adams,et al.  A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine Aspirin Stroke Study Group. , 1989, The New England journal of medicine.

[62]  V. Hachinski,et al.  THE CANADIAN AMERICAN TICLOPIDINE STUDY (CATS) IN THROMBOEMBOLIC STROKE , 1989, The Lancet.

[63]  P. Théroux,et al.  Aspirin, heparin, or both to treat acute unstable angina. , 1988, The New England journal of medicine.

[64]  J. Boissel,et al.  Multicenter Double-Blind Study of Ticlopidine in the Treatment of Intermittent Claudication and the Prevention of its Complications , 1988, Angiology.

[65]  L Schwartz,et al.  Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty. , 1988, The New England journal of medicine.

[66]  Thomas E. Moritz,et al.  Improvement in early saphenous vein graft patency after coronary artery bypass surgery with antiplatelet therapy: results of a Veterans Administration Cooperative Study. , 1988, Circulation.

[67]  P. Rigo,et al.  Prevention of aorta-coronary bypass graft occlusion. Beneficial effect of ticlopidine on early and late patency rates of venous coronary bypass grafts: a double-blind study. , 1987, The Journal of thoracic and cardiovascular surgery.

[68]  J. Webster,et al.  Random control trial of a short course of aspirin and dipyridamole (Persantin) for femorodistal grafts , 1987, The British journal of surgery.

[69]  H. Sewell,et al.  CYTOCHROME P-450 IMMUNOLOCALISATION IN HUMAN LIVER , 1986, The Lancet.

[70]  D. Sackett,et al.  Aspirin, sulfinpyrazone, or both in unstable angina. Results of a Canadian multicenter trial. , 1985, The New England journal of medicine.

[71]  W. Kannel,et al.  Update on Some Epidemiologic Features of Intermittent Claudication: The Framingham Study , 1985, Journal of the American Geriatrics Society.

[72]  P. Rigo,et al.  Effect of ticlopidine on saphenous vein bypass patency rates: a double-blind study. , 1984, The Annals of thoracic surgery.

[73]  M. LeWinter,et al.  Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study. , 1983, The New England journal of medicine.

[74]  C. Forbes,et al.  RELATION OF ATRIAL FIBRILLATION AND HIGH HAEMATOCRIT TO MORTALITY IN ACUTE STROKE , 1983, The Lancet.

[75]  Lippincott Williams Wilkins,et al.  Persantine and aspirin in coronary heart disease. The Persantine-Aspirin Reinfarction Study Research Group. , 1980, Circulation.

[76]  Persantine and Aspirin in Coronary Heart Disease , 1980 .

[77]  J. Mann,et al.  Intermittent claudication: prevalence and risk factors. , 1978, British medical journal.

[78]  L. Wilhelmsen,et al.  SMOKING AND MYOCARDIAL INFARCTION , 1975, The Lancet.

[79]  E. Veys,et al.  HL-A AND INFECTIVE SACROILEITIS , 1974 .

[80]  R. Hone,et al.  Letter: Methicillin-resistant Staphylococcus aureus. , 1974, Lancet.

[81]  S. Marsch,et al.  A randomized comparison of clopidogrel and aspirin versus ticlopidine and aspirin after the placement of coronary artery stents. , 2003, Journal of the American College of Cardiology.

[82]  E. Ohman,et al.  Antithrombotic therapy in patients undergoing percutaneous coronary intervention. , 2001, Chest.

[83]  David R. Wood,et al.  Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme. , 2001, European heart journal.

[84]  P. R. R. Ecurrent,et al.  EFFECTS OF CLOPIDOGREL IN ADDITION TO ASPIRIN IN PATIENTS WITH ACUTE CORONARY SYNDROMES WITHOUT ST-SEGMENT ELEVATION , 2001 .

[85]  G. de Gaetano Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Collaborative Group of the Primary Prevention Project. , 2001, Lancet.

[86]  J. W. Schaeffer,et al.  ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). , 2000, Journal of the American College of Cardiology.

[87]  Y. Wang,et al.  Ticlopidine-associated aplastic anemia. A case report and review of literature. , 1998, Annals of hematology.

[88]  J. Mason,et al.  North of England evidence based guideline development project: guideline on the use of aspirin as secondary prophylaxis for vascular disease in primary care. North of England Aspirin Guideline Development Group. , 1998, British medical journal.

[89]  Philippe Amouyel,et al.  A European Society of Cardiology survey of secondary prevention of coronary heart disease: Principal results. , 1997 .

[90]  EUROASPIRE. A European Society of Cardiology survey of secondary prevention of coronary heart disease: principal results. EUROASPIRE Study Group. European Action on Secondary Prevention through Intervention to Reduce Events. , 1997, European heart journal.

[91]  The efficacy of aspirin in patients with atrial fibrillation. Analysis of pooled data from 3 randomized trials. The Atrial Fibrillation Investigators. , 1997, Archives of internal medicine.

[92]  D. Clement A randomised, blinded, trial of Clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE) , 1996 .

[93]  A. Schafer Antiplatelet therapy. , 1996, The American journal of medicine.

[94]  4th American College of Chest Physicians Consensus Conference on Antithrombotic Therapy. Tucson, Arizona, April 1995. Proceedings. , 1995, Chest.

[95]  M. Kindermans,et al.  Results of EMATAP: a double-blind placebo-controlled multicentre trial of ticlopidine in patients with peripheral arterial disease. , 1994, Nouvelle revue francaise d'hematologie.

[96]  P. Teirstein,et al.  A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. , 1994, The New England journal of medicine.

[97]  H. White,et al.  Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation : stroke prevention in atrial fibrillation II study. Commentary , 1994 .

[98]  Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration. , 1994, BMJ.

[99]  Thomas E. Moritz,et al.  Implications of preoperative administration of aspirin in patients undergoing coronary artery bypass grafting. Department of Veterans Affairs Cooperative Study on Antiplatelet Therapy. , 1990, Journal of the American College of Cardiology.

[100]  Sarah Parish,et al.  Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2.ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. , 1988, Journal of the American College of Cardiology.

[101]  W. Schweizer,et al.  The Basle longitudinal study: report on the relation of initial glucose level to baseline ECG abnormalities, peripheral artery disease, and subsequent mortality. , 1979, Journal of chronic diseases.